P-REALITY X: prolonging metastatic breast cancer survival by adding palbociclib to an aromatase inhibitor

Our partnered journal Future Oncology recently published a plain language summary of publication describing a real-world database analysis exploring how adding palbociclib to an aromatase inhibitor could prolong the life of people with metastatic HR+/HER2– breast cancer in routine clinical practice.  Abstract What is this summary about? This is a summary of an article about a study called “P-REALITY X” that was published in the medical journal npj Breast Cancer in October 2022. “P-REALITY X” stands for Palbociclib REAl-world first-LIne comparaTive effectiveness studY eXtended. This study used information from a database to look at whether adding a second treatment (palbociclib)...